Posts tagged ‘Competitive Intelligence’
Sally Church on Pharma Strategy Blog will be providing live coverage of the AACR PI3-Kinase conference that starts today in San Francisco.
Sally AKA @MaverickNY will be live tweeting from the event that starts at 7pm (california time) today, Thursday, February 24 and runs through Sunday morning, February 27. The Cover it Live widget on her blog will be aggregating all the tweets that use the conference hashtag #PI3K, so if you are unable to be in San Francisco, you can follow what’s happening by clicking here.
This AACR special conference has an impressive line-up of leading key opinion leaders and experts in the field. The keynote session this evening is on “Targeting PI3K/mTOR in breast cancer” by Jose Baselga, from Mass General. The session chair is Lewis Cantley.
Some of the new products in development that will be discussed at the meeting include: GSK2126458, INK1117, AZD8055, MK-2206 and SAR245408 (XL147). If you are interested in purchasing an Icarus Consultants in-depth meeting report, do contact us.
Today’s announcement that Gilead Sciences is acquiring Calistoga pharmaceuticals for $375M shows that acquisition remains a key strategy for companies looking to add promising new drugs to their pipeline.
Calistoga’s CAL-101 is a PI3-kinase inhibitor that targets cancer and inflammatory diseases. You can read more about the acquisition of Calistoga by Gilead on Biotech Strategy Blog.
Today on Pharma Strategy Blog, Sally Church comments on the sheer volume of data associated with modern science, a topic considered by Science magazine in their February 11, 2011 issue.
What makes this close to our heart at Icarus Consultants, is that what we do for a living as a marketing strategy company focusing on the life sciences, pharmaceutical and biotechnology industries, is process a lot of data. Anybody can provide you with a data dump of all the posters or presentations from a scientific meeting, but what does this data mean, what do the key opinion leaders think and what are the strategic implications that come out of it?
In the internet era, the amount of data available to us is increasing, but we are faced by more demands on our time. That’s why people often hire us, not to do what they cannot do themselves, but what they don’t have the time to do. It takes time to process data and generate analysis and insight.
More perspective on this topic can be found on Pharma Strategy Blog.
Published by Sally Church on Pharma Strategy Blog
U.S. Supreme Court to decide if only statistically significant adverse events need to be disclosed to investors
January 11th, 2011
Daedalus
Published by Pieter Droppert on Biotech Strategy Blog
Published by Pieter Droppert on Biotech Strategy Blog
Luke Timmerman on xconomy.com refers to Sally Church’s predictions published on Pharma Strategy Blog of what’s hot at ASH in 2010:
Icarus Consultants will be at the American Society of Hematology (ASH) annual meeting in Orlando this week, from Friday December 3 to Tuesday 7 December. If you are attending and would like to meet up for a chat or capabilities discussion, please contact us.